Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 5Leukemia, Myeloid, Acute 3Uveal Melanoma 2Stomach Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1Lymphoma, Non-Hodgkin 1Liver Neoplasms 1Leiomyosarcoma 1HER2 Negative Metastatic Breast Cancer 1Glioma 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma 1Advanced Solid Cancers 1Advanced Pancreatic Cancer 1

Interventions

Bevacizumab 187Fluorouracil 150Leucovorin 135Cetuximab 127Irinotecan 114Oxaliplatin 108pembrolizumab 96Capecitabine 82IFL protocol 53Panitumumab 43Nivolumab 43regorafenib 42Folfox protocol 39Gemcitabine 30trifluridine tipiracil drug combination 27Cisplatin 24Carboplatin 24atezolizumab 23Pemetrexed 20Paclitaxel 20Drug Therapy 20130-nm albumin-bound paclitaxel 17Trastuzumab 14encorafenib 13Trifluridine 13Ipilimumab 13HMPL-013 13tislelizumab 12spartalizumab 11Docetaxel 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Colorectal Neoplasms × ADI PEG20 × Clear all
NCT02102022 2022-04-25

Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma

Polaris Group

Phase 1/2 Terminated
140 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡